Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on April 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Christopher Gibson will leave Recursion’s Board after the 2026 Annual Meeting.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Christopher Gibson will leave Recursion’s Board after the 2026 Annual Meeting
- Gibson’s departure includes relinquishing Board Chair and committee roles after his term expires
- No disagreement with company operations, policies, or practices cited as the reason
- Leadership transition may affect governance and strategic oversight during Recursion’s next phase
Item EX-99.1 · Exhibit EX-99.1
- Founder and Chair Chris Gibson leaving board after June 2026 term; no re-election planned
- Gibson continuing as strategic advisor, preserving founder expertise during leadership transition
- Board transition follows CEO Najat Khan’s recent leadership shift, with continuity emphasized
- No disclosed changes to pipeline strategy, partnerships, or company financial obligations
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.